


The slide features a background with a dark, starry space scene on the left and a teal gradient on the right. The CureVac logo, consisting of the word "CUREVAC" in a stylized font with a checkmark-like shape, and the tagline "the RNA people®" in a script font, is positioned in the upper right. A white rectangular box with an orange border contains the main title. To the right of this box is a large orange square, and below it is a smaller orange square. In the bottom right corner, there is a dark grey square.

**CureVac's mRNA based
Vaccine Candidate against
SARS-CoV-2**

Data update September 22nd, 2020
- STRICTLY CONFIDENTIAL -

Project update: Recent Ph1 and hamster results are encouraging and dose escalation continues in order to select the final dose

Previously shared, with data as of September 28th

CureVac's mRNA platform and pre-clinical data

CVnCoV Clinical Development Plan and available clinical data

Manufacturing footprint and delivery plan

CVnCoV presentation and target shelf-life at 2-8°C

Focus of today's update

1. Update on available Phase 1 data

Reactogenicity profile at higher doses

IgG titers at higher doses

VNTs across the dose range: methodology improvements suggest that dose should be at least 8µg, and require continuing exploration towards higher doses before final dose selection for pivotal trials

2. Hamster data suggest that CVnCoV has the potential to protect lung disease and reduce viral load in nose and throat

3. Clinical development plan supported by EMA feedback

4. Progress on manufacturing network and updated capacity estimates at higher doses



- Strictly confidential -

**1. Update on available Phase 1
clinical data: reactogenicity and
immunogenicity**

(10)(1c)

(10)(1c)

(10)(1c)

(10)(1c)

(10)(1c)


(10)(1c)

(10)(1c)

(10)(1c)

(10)(1c)


Key next steps – near term events towards dose selection






2. Insights from animal model data

Hamster Challenge Model: ELISA responses are detectable after 1st dose and Virus Neutralizing Titers after 2nd dose in Hamsters





High VNTs after 2 vaccinations at 10 µg



Encoded protein: SARS-CoV-S full length K₉₈₆P, V₉₈₇P

Evaluation: ELISA IgG & VNTs: Cytopathic effect (CPE) based microneutralization at Viroclinics

CVnCoV Provides Protection of the Lungs and Leads to Reduced Viral Titers in Nasal Turbinates




Viral loads in lungs and nasal turbinates

All animals show protection of the lungs comparable to infected positive control at 10 µg

Trend for reduced nasal viral loads in 3 out of 5 animals at 10µg


Evaluation: live virus titration from lung and nasal turbinates homogenates



September 24, 2020

| 16


CVnCoV is able to decrease viral levels in the throat




Lung Protection of CVnCoV - Reduced Percentage of Affected Lung Tissue Upon Challenge Infection



Gross lung pathology at day 7 after challenge
% affected lung pathology




Lung protection - no evidence of Enhanced Disease: Reduced gross lung pathology compared to the control groups






3. Clinical development plan supported by EMA feedback

CVnCoV - Progress and path towards EMA approval



(10)(1c)



(10)(1c)

(10)(1c)

